

PharmLabs San Diego Certificate of Analysis



Sample TRE House - Microdose Mushroom Gummies - Sour Apple

|   |                       |                       |
|---|-----------------------|-----------------------|
| Sample ID SD260120-026 (131712)           | Matrix Edible         | Batch ID THMG-SA1431  |
| Tested for Market Place Ventures LLC      |                       |                       |
| Sampled -                                 | Received Jan 20, 2026 | Reported Jan 21, 2026 |
| Analyses executed 4AD, AMU, TRY, PSY, SDR | Unit Mass (g) 84.398  | Num. of Servings 15   |
|   |                       | Serving Size (g) 5.63 |

Laboratory note: This sample contains an Unidentified Peak that PharmLabs does not currently test for. COA Update: 1/21/26 - Sample Name and Batch ID updated per client request.

4AD - 4AD Tryptamines

Analyzed Jan 20, 2026 | Instrument HPLC VWD | Method SOP-4AD  
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte                      | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit | Sample photography |
|------------------------------|---------|---------|----------|-------------|-------------------|----------------|--------------------|
| Mescaline (MES)              | 0.19    | 0.584   | ND       | ND          | ND                | ND             |                    |
| N-methyl Tryptamine (NMT)    | 0.004   | 0.013   | ND       | ND          | ND                | ND             |                    |
| 4-Hydroxy-MET (4-HO-MET)     | 0.013   | 0.04    | ND       | ND          | ND                | ND             |                    |
| n,n Dimethyltryptamine (DMT) | 0.015   | 0.048   | ND       | ND          | ND                | ND             |                    |
| Psilocetin (PSLA)            | 0.015   | 0.044   | ND       | ND          | ND                | ND             |                    |
| 4-Hydroxy-DET (4-HO-DET)     | 0.014   | 0.042   | ND       | ND          | ND                | ND             |                    |
| 4-Acetoxy-MET (4-AcO-MET)    | 0.018   | 0.053   | ND       | ND          | ND                | ND             |                    |
| 4-Acetoxy-DET (4-AcO-DET)    | 0.004   | 0.011   | ND       | ND          | ND                | ND             |                    |
| 4-Bromo-DMP (2C-B)           | 0.19    | 0.576   | ND       | ND          | ND                | ND             |                    |

AMU - Amanita Muscaria

Analyzed Jan 20, 2026 | Instrument HPLC VWD | Method SOP-039 AMU  
The expanded Uncertainty of the Amanita Muscaria analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte              | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|----------------------|---------|---------|----------|-------------|-------------------|----------------|
| Ibotenic Acid (IBOa) | 1.025   | 3.105   | ND       | ND          | ND                | ND             |
| Muscimol (MUOL)      | 0.19    | 0.576   | ND       | ND          | ND                | ND             |

TRY - Tryptamine

Analyzed Jan 20, 2026 | Instrument HPLC VWD | Method SOP-TRY  
The expanded Uncertainty of the Tryptamine analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte              | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|----------------------|---------|---------|----------|-------------|-------------------|----------------|
| Norbaeocystin (NORB) | 0.01    | 0.029   | ND       | ND          | ND                | ND             |
| Baeocystin (BAEO)    | 0.01    | 0.029   | ND       | ND          | ND                | ND             |
| Aeruginascin (AERU)  | 0.007   | 0.022   | ND       | ND          | ND                | ND             |
| Norpsilocin (NORP)   | 0.003   | 0.009   | ND       | ND          | ND                | ND             |

PSY - Psilocybin & Psilocin

Analyzed Jan 20, 2026 | Instrument HPLC VWD | Method SOP-PSY  
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte           | LOD ppm | LOQ ppm | Result % | Result mg/g | Result mg/Serving | Result mg/Unit |
|-------------------|---------|---------|----------|-------------|-------------------|----------------|
| Psilocybin (PSCY) | 0.007   | 0.019   | ND       | ND          | ND                | ND             |
| Psilocin (PSCI)   | 0.003   | 0.009   | ND       | ND          | ND                | ND             |

UI Unidentified  
ND Not Detected  
N/A Not Applicable  
NT Not Reported  
LOD Limit of Detection  
LOQ Limit of Quantification  
<LOQ Detected  
>ULOL Above upper limit of linearity  
CFU/g Colony Forming Units per 1 gram  
TNTC Too Numerous to Count



DEA license: RP0611043  
ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
Wed, 21 Jan 2026 15:26:32 -0800

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.